As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.